Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > August 18, 2020
Daily News
August 18, 2020
- Novo to Skip August Listing for 1st Oral GLP Agent Rybelsus
August 18, 2020
- Pfizer Japan Takes Generic Contenders to Court over Lyrica Patent
August 18, 2020
- 22 Firms Get Approval for Lyrica Generics towards December Listing, Pfizer AG Included
August 18, 2020
- Takeda to Introduce Early Retirement Program for Japan Staffers
August 18, 2020
- Fujifilm to Make Antigen for Novavax’s COVID-19 Vaccine for UK Govt
August 18, 2020
- Japan Pharma Market Down 2.5% in April-June: IQVIA
August 18, 2020
- MHLW Grants Orphan Drug Status to Janssen’s Ibrutinib, 6 Other APIs
August 18, 2020
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…